P-glycoprotein and Amyloid in M. Alzheimer

• Conditions: Alzheimer's disease; dementia; 10014623

• Registration Number: NL-OMON31892
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

- Meet the NINCDS-ADRDA criteria for probable Alzheimer's disease
- Mild form of dementia (MMSE 19-22)
- Older than 50 years
Healthy controls do not meet NINCDS-ADRDA or MCI criteria.

Exclusion Criteria

- Use of medication that could influence Pgp function, e.g. digoxin, cyclosporin, amiodarone, steroïds, quinidin, colchicin, etoposide, antiestrogensn and atorvastatin.
- Vasculair braindisease or otherwise braindiseases which could influence cerebral metabolism or perfusion.
- Significant kidney or liverdisase.
- Neurological symptoms not in agreement with a diagnosis of Alzheimer's disease.
- Pregnancy.
- Prior (excessive) radiation exposure in the same year (including radiological assistants or nuclear medicine employees).

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary study parameters are the Pgp function, A&beta; accumalation and their<br /><br>correlation in Alzheimer's disease and healty controls. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable. </p><br>